Medicus Pharma (MDCX) EBITDA (2024 - 2025)
Medicus Pharma (MDCX) posted EBITDA of -$15.1 million for Q4 2025, down 754444650.0% quarter-over-quarter from -$2.0 in Q3 2025, and down 326.66% year-on-year from $6.7 million in Q4 2024.
Medicus Pharma (MDCX) EBITDA (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported EBITDA for 2 consecutive years, with -$15.1 million the latest figure, recorded in Q4 2025.
- EBITDA for Q4 2025 came in at -$15.1 million, down 326.66% year-over-year; the trailing twelve-month figure through Dec 2025 was -$26.2 million (down 136.82% YoY), and the FY2025 annual result was -$47.3 million, down 323.94% from the prior year.
- EBITDA was -$15.1 million for Q4 2025 at Medicus Pharma, down from -$2.0 in the prior quarter.
- Over five years, EBITDA peaked at -$2.0 in Q3 2025 and troughed at -$15.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 9.50 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 6.36 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.99 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 2.71 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | -15.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.09 Mn |
| Sep 30, 2025 | -2.00 |
| Jun 30, 2025 | -6.02 Mn |
| Mar 31, 2025 | -5.13 Mn |
| Dec 31, 2024 | -3.54 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -1.71 Mn |